Zhejiang Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ZHEJIANG
ZHEJIANG has twenty-three approved drugs.
There are two tentative approvals on ZHEJIANG drugs.
Drugs and US Patents for Zhejiang
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Yongtai | ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | CAPSULE, DELAYED REL PELLETS;ORAL | 217022-002 | Dec 27, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Jingxin | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 206513-002 | Mar 1, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Jutai Pharm | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 214110-001 | Jul 26, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Jutai Pharm | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 214110-002 | Jul 26, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Poly Pharm | BRIVARACETAM | brivaracetam | SOLUTION;ORAL | 218494-001 | Feb 23, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zhejiang Yongtai | ROSUVASTATIN CALCIUM | rosuvastatin calcium | TABLET;ORAL | 212059-001 | Nov 4, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

